FDA Releases Draft Guidance On CMC For Individualized ASO Therapies
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO)...
Source: pharmaceuticalonline.com
Stay updated with breaking news from Procedural Recommendations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO)...
To eliminate ineffectiveness due to genetic differences, clinical trials of individual patients, described as an “N of 1”...
To eliminate ineffectiveness due to genetic differences, clinical trials of individual patients, described as an “N of 1”...